ChemBriefKasvu Therapeutics Pursues Novel Neuroplasticity Target for Depression
Kasvu Therapeutics secured €30 million in Series A funding to advance KTX-0141 for major depressive disorder. The startup targets the TrkB receptor to induce neuroplasticity without the hallucinogenic
cen · 2026-09-24 00:00 UTC